Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.

• Over 700 patients with HIV-associated wasting while receiving HAART were randomly assigned to double-blind treatment for 12 weeks with recombinant human growth hormone (rhGH) daily or on alternate days, or to placebo. Maximum exercise intensity increased by a median of 2.35kJ in the alternate-days group and 2.60 kJ in the daily group but decreased by 0.25kJ in the placebo group. The median difference between the daily and placebo groups was 2.85 kJ (P < .0001). These improvements suggest that rhGH treatment may enable patients with wasting to perform activities of daily living that would be exhausting without rhGH treatment.

Nyckelord

Adult

Antiretroviral Therapy

Highly Active

methods

Body Composition

drug effects

Dose-Response Relationship

Drug

Double-Blind Method

Drug Administration Schedule

Drug Therapy

Combination

Exercise Tolerance

drug effects

Female

Follow-Up Studies

HIV Wasting Syndrome

diagnosis

drug therapy

mortality

Human Growth Hormone

administration & dosage

Humans

Male

Middle Aged

Probability

Recombinant Proteins

administration & dosage

Reference Values

Risk Assessment

Treatment Outcome

Publikations- och innehållstyp

ref (ämneskategori)

art (ämneskategori)